Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics
The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).
LENVIMA® (lenvatinib) HCP Website | Overall Survival (OS)
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
PSE investigates the correlation between OS and PFS at ESMO 2017
Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer
Extrapolation from Progression-Free Survival to Overall Survival in Oncology
1. Why is Overall Survival (OS), in months, | Chegg.com
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
Figure 1. Overall survival (OS) curve according to performance status(PS) of the study cohort of patients with advanced non-small cell lung cancer (mean OS of PS 0= 18.41, PS 1= 10.76, PS
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
Final overall survival (OS) data from FLAURA trial - YouTube
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/eb56a0ed555af54134d5949c8b856bff15592fe4/3-Figure1-1.png "PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar")
PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Final KEYNOTE 177 overall survival data for MSI-H/dMMR metastatic colorectal cancer - Onco Americas
Kaplan-Meier survival curve for overall survival (OS) after total... | Download Scientific Diagram
VENCLEXTA® (venetoclax tablets) | VIALE-A Trial Overall Survival Data
REVEL Trial Overall Survival for | CYRAMZA® (ramucirumab)
